Veru Inc
NASDAQ:VERU
Intrinsic Value
Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. [ Read More ]
The intrinsic value of one VERU stock under the Base Case scenario is 0.1495 USD. Compared to the current market price of 0.9182 USD, Veru Inc is Overvalued by 84%.
Valuation Backtest
Veru Inc
Run backtest to discover the historical profit from buying and selling VERU stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Balance Sheet Decomposition
Veru Inc
Current Assets | 45.1m |
Cash & Short-Term Investments | 34.7m |
Receivables | 2.8m |
Other Current Assets | 7.6m |
Non-Current Assets | 26.7m |
Long-Term Investments | 346.4k |
PP&E | 5.5m |
Intangibles | 6.9m |
Other Non-Current Assets | 14m |
Current Liabilities | 9.6m |
Accounts Payable | 2.5m |
Accrued Liabilities | 5.6m |
Other Current Liabilities | 1.5m |
Non-Current Liabilities | 17m |
Long-Term Debt | 8.8m |
Other Non-Current Liabilities | 8.2m |
Earnings Waterfall
Veru Inc
Revenue
|
13.5m
USD
|
Cost of Revenue
|
-8.9m
USD
|
Gross Profit
|
4.6m
USD
|
Operating Expenses
|
-47.8m
USD
|
Operating Income
|
-43.2m
USD
|
Other Expenses
|
7.4m
USD
|
Net Income
|
-35.8m
USD
|
Free Cash Flow Analysis
Veru Inc
USD | |
Free Cash Flow | USD |
VERU Profitability Score
Profitability Due Diligence
Veru Inc's profitability score is 11/100. The higher the profitability score, the more profitable the company is.
Score
Veru Inc's profitability score is 11/100. The higher the profitability score, the more profitable the company is.
VERU Solvency Score
Solvency Due Diligence
Veru Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Veru Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VERU Price Targets Summary
Veru Inc
According to Wall Street analysts, the average 1-year price target for VERU is 3.5088 USD with a low forecast of 1.212 USD and a high forecast of 5.25 USD.
Ownership
VERU Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
VERU Price
Veru Inc
Average Annual Return | 42.96% |
Standard Deviation of Annual Returns | 75.98% |
Max Drawdown | -98% |
Market Capitalization | 134.4m USD |
Shares Outstanding | 146 384 000 |
Percentage of Shares Shorted | 9.68% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. The company is headquartered in Miami, Florida and currently employs 252 full-time employees. The firm is focused on developing medicines for the management of breast and prostate cancers. The firm's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. The company has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
Contact
IPO
Employees
Officers
The intrinsic value of one VERU stock under the Base Case scenario is 0.1495 USD.
Compared to the current market price of 0.9182 USD, Veru Inc is Overvalued by 84%.